EPIX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by ESSA Pharma Inc.
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into ESSA Pharma Inc. for potential securities fraud violations. This follows ESSA's announcement of ending its Phase 2 trial for a prostate cancer treatment.
November 11, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ESSA Pharma Inc. is under investigation by Levi & Korsinsky for possible securities fraud violations after halting a Phase 2 trial for a prostate cancer treatment.
The investigation into potential securities fraud and the halting of a significant clinical trial could negatively impact investor confidence and the stock price of ESSA Pharma in the short term. Legal and regulatory issues often lead to increased volatility and potential sell-offs.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100